Drug class | Drugs | Interaction |
Adrenergic neurone blockers | Debrisoquine, guanethidine, bretylium. | Antagonism of hypotensive effects |
Antipsychotics | Clozapine, loxapine, olanzapine, oxypertine, risperidone,
pimozide
sulpiride, phenothiazines (chlorpromazine, levomepromazine,
(methotrimeprazine), promazine, pericyazine
pipotiazine, thioridazine
fluphenazine, perphenazine, prochlorperazine, trifluoperazine),
butyrophenones (benperidol, haloperidol) thioxanthenes
(flupentixol, zuclopenthixol), amisulpride, quetiapine,
zotepine.
| Antagonism of pressor action |
Clonidine | Clonidine | Serious adverse effects have been reported with concomitant
use of methylphenidate and clonidine (e.g. ****), although a causal
relationship has not been established and the safety of using a
combination of methylphenidate and clonidine has not been evaluated
systematically. |
Doxapram | Doxapram | Risk of hypertension |
MAOIs | Isocarboxazid, Phenelzine, Tranylcypromine.
| Risk of hypertensive crisis (Should not use concomitantly or within 14 days of
discontinuation) |
Moclobemide | Moclobemide | Risk of hypertensive crisis |
Oxytocin | Oxytocin | Hypertension due to enhanced vasopressor effect of
vasoconstrictor sympathomimetics |
Phenobarbital | Phenobarbital | Possibly increased plasma-phenobarbital and methylphenidate
concentration |
Phenytoin | Phenytoin | Increased plasma-phenytoin and methylphenidate
concentration |
Primidone | Primidone | Possibly increased plasma-primidone and methylphenidate
concentration |
Selective serotonin reuptake inhibitors | Citalopram, fluoxetine, fluvoxamine maleate, paroxetine,
sertraline. | Metabolism of SSRI may be inhibited |
Tricyclic antidepressants | Amitriptyline, amoxapine, clomipramine, dosulepin (dothiepin),
doxepin, imipramine, lofepramine, nortriptyline,
trimipramine.
| Metabolism of tricyclic may be inhibited |